MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
February 01 2023 - 4:05PM
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell therapeutics and to
support innovative cell-based research, today announced that it
will release financial results for the fourth quarter and full year
2022 after the U.S. market close on Wednesday, March 15th, 2023.
Company management will host a conference call to discuss financial
results at 4:30 p.m. Eastern Time.
Earnings Conference Call DetailsInvestors
interested in listening to the conference call are required to
register online. It is recommended to register at least a day in
advance. A live and archived webcast of the event will be available
on the “Events” section of the MaxCyte website at
https://investors.maxcyte.com/.
Company management will also participate in the following
investor conferences:
- BIO CEO & Investor Conference Tuesday, February 7th at 3:15
p.m. Eastern Time
- BTIG MedTech, Digital Health, Life Science & Diagnostic
Tools ConferenceTuesday, February 14th
- 43rd Annual Cowen Healthcare Conference Tuesday, March 7th at
11:10 a.m. Eastern Time
A live and archived webcast of the Cowen presentation will be
available on the “Events” section of the MaxCyte investor relations
website at https://investors.maxcyte.com/.
About MaxCyteMaxCyte is a
leading, cell-engineering focused company providing enabling
platform technologies to advance the discovery, development and
commercialization of next-generation cell therapeutics and to
support innovative, cell-based research. Over the past
20 years, we have developed and commercialized our proprietary
Flow Electroporation® platform, which facilitates complex
engineering of a wide variety of cells. Our ExPERT™ platform,
which is based on our Flow Electroporation technology, has been
designed to support the rapidly expanding cell therapy market and
can be utilized across the continuum of the high-growth cell
therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™ GTx™ and VLx™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
MaxCyte Contacts:
US IR AdviserGilmartin
GroupDavid Deuchler, CFA+1 415-937-5400ir@maxcyte.com
Nominated Adviser and Joint Corporate
BrokerPanmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500
UK IR AdviserConsilium Strategic
CommunicationsMary-Jane Elliott / Chris Welsh+44 (0)203
709 5700maxcyte@consilium-comms.com
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024